Continuation of trastuzumab beyond disease progression.
Montemurro
Filippo
F
Faggiuolo
Roberto
R
Redana
Stefania
S
Donadio
Michela
M
Minischetti
Monica
M
Durando
Antonio
A
Vietti-Ramus
Guido
G
Buosi
Roberta
R
Aglietta
Massimo
M
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003657:Decision Making; D018450:Disease Progression; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab